Description

This PACE snapshot session is an initiative of the PACE foundation as part of its mission, which includes the review, exchange and assimilation of important new data underlying cardiovascular disease & diabetes and accelerate this information into clinical practice. The aim of this meeting is to provide expert physicians with a state of the art and comprehensive overview of different novel interventions in the future management of cardiovascular disease. The session will provide expert physicians with a platform for discussion, debate and exchange. The session is designed in a format with multiple short introductions by leading experts, covering a broad field of innovations in cardiovascular risk factor management , such as hypertension, lipid management, anticoagulation and diabetes, including time for discussion and debate.

Meeting objectives

• To review and discuss new data and developments on the pathophysiology of cardiovascular disease and its relevance to treatment strategies and outcomes.
• To understand the pharmacologic and clinical rationale for various new treatment options in the management of cardiovascular disease.
• To develop a consensus on practical guidelines for clinical magement of the coronary artery disease patient

View brief CME webcasts sessions with each of the faculty members

ACS & Diabetes Brief-CME: A review by Prof. John Betteridge, UCL, London on the current status of drugs targeting the hormone nuclear receptors, such as pioglitazone (PPAR-y) and aleglitazar (dual PPAR) and their potential impact on outcomes in CVD.	Targeting CV risk: Brief-CME: View Prof. John Deanfield, London, discuss the central role of the endothelium in detecting atherosclerosis and CV disease before its clinical stage and opportunities to evaluate the impact of new drug therapies.
HDL-c: Latest insights and opinion on CETP as target for intervention Brief-CME. Prof. Philip Barter, The Heart Institute Sydney, Australia, chairman of IAS, provides his opinion on the development of CETP inhibitors. Now development of 2 initial compounds has failed the hypothesis remains worth testing and large scale clinical outcomes trials with anacetrapib and evacetrapib are underway.	ACS and Lipids: HDL Infusion and delipidation as standard treatment for ACS Dr. Bryan Brewer, Washington DC, USA, discusses the potential role of HDL infusion in the coronary plaque to reduce residual cardiovascular risk in patients with ACS.
The future of hypertension management:The role of new interventions Brief-CME. Prof. Bryan Williams outlines some of the key areas of innovation in the management of high blood pressure, like potential new drug therapies as AT2 receptor agonists and dual ARB/NEP inhibition (ARNI) and also new device therapies as Renal denervation and Carotid Baroreceptor Stimulation.	LDL-c, Should we go lower?: Novel therapies, Novel promises? Brief-CME. Watch prof. John Kastelein, Amsterdam, review novel interventions in lipid management beyond statin therapy, such as PCSK9 inhibitors, cholesterol absorption inhibition, mRNA inhibitors and MTP inhibitors.
Inflammation: The link between risk factors and atherosclerosis? Brief-CME: Prof. Ulf Landmesser, Zurich, Switzerland is discussing the potential role of inflammation in the vessel wall in the causal process of atherosclerosis and interventions targeted to reduce inflammation as currently tested in the CANTOS trial.	What is new in Anti-coagulation in AF and ACS Brief-CME. Prof. Freek Verheugt, Amsterdam, The Netherlands, discusses the potential role of New Oral Anticoagulants as alternative to warfarin in the management of Atrial Fibrillation.

View PPT presentations with key slides presented by the faculty

The future of hypertension management The role of new interventions Presented by Prof Bryan Williams, University College London At PACE Snapshot meeting, August 24, 2012 in Munich	LDL-c, Should we go lower? Novel Therapies, Novel Promises? Presented by prof John Kastelein, Academic Medical Centre, Amsterdam At PACE Snapshot meeting, August 24, 2012 in Munich
HDL raising therapies: Latest insights and opinion on CETP as target for intervention. Presented by professo Philip Barter, The Heart Research Institute, Sydney, Australia At PACE Snapshot meeting, August 24, 2012 in Munich	What is new and coming in anticoagulation and ACS, AF Presented by professor Freek Verheugt, OLVG, Amsterdam, The Netherlands At PACE Snapshot meeting, August 24, 2012 in Munich
Inflammation: The link between risk factors and atherosclerosis? Presented by professor Ulf Landmesser, University Hospital Zurich, Switzerland At PACE Snapshot meeting, August 24, 2012 in Munich	HDL & ACS HDL infusion and delipidation as standard treatment for ACS Presented by dr Bryan Brewer, Medstar Resaerch Institute, Washington, USA At PACE Snapshot meeting, August 24, 2012 in Munich
ACS & Diabetes Potential role of new antidiabetic therapies Presented by prof John Betteridge, University College London, United Kingdom At PACE Snapshot meeting, August 24, 2012 in Munich

Agenda PACE Snapshot 2012

18:45 – 18:55     Welcome and opening remarks Chairman:
                              John Deanfield, MD,  University College London, United Kingdom
                              John Kastelein, MD, Academic Medical Centre, Amsterdam,The Netherlands

Novel insights in atherosclerosis and vascular biology

18:55 – 19:10      Targeting cardiovascular risk: The endothelium as final common pathway for interventions
                               John Deanfield, MD,  University College London, United Kingdom

19:10 – 19:25      Inflammation: The link between risk factors and atherosclerosis?
                               Ulf Landmesser, MD, University Hospital Zurich, Switzerland

Novel interventions targeting blood pressure

19:25 – 19:45     The future of hypertension management:The role of new interventions 
                               Bryan Williams, MD, University College London, United Kingdom

19:45 – 20:00      Discussion

ACS & Atrial Fibrillation: Novel therapies in cardiology

20:00 – 20:15     What is new and coming in anticoagulation and ACS and AF: State of the art
                               Freek Verheugt, MD, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands

20:15 – 20:30     ACS & Diabetes: potential role of new antidiabetic therapies
                              John Betteridge, MD, University College London, United Kingdom

20:30 – 20:45     ACS and Lipids: HDL Infusion and delipidation as standard treatment for ACS
                              Bryan Brewer, MD, Medstar Research Institute, Washington DC, USA

Innovations in Lipid management

20:45 – 21:00    LDL-c, Should we go lower?, Novel therapies, more promises 
                             John Kastelein, Academic Medical Centre, Amsterdam,The Netherlands

21:00 – 21:15    HDL raising therapies: latest insights and opinion on CETP as target for intervention 
                             Philip Barter, MD, The Heart Research Institute, Sydney, Australia

21:15 – 21:30    Prevention of CV disease by novel Triglyceride lowering therapies?
                             Michael Davidson, MD, University of Chicago, Chicago, IL, USA

21:00 – 22:00    Discussion